Litigation Details for Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Docket	1:17-cv-01808	Date Filed	2017-12-15
Court	District Court, D. Delaware	Date Terminated	2018-02-12
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,011,068; 6,031,003; 6,211,244; 6,313,146; 7,829,595; 9,375,405
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Amgen Inc. v. Barr Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-15				External link to document
2017-12-14	1		Book lists U.S. Patent Nos. 6,011,068 (“the ’068 patent”), 6,031,003 (“the ’003 patent”), 6,313,146 (“… infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) under the Patent Laws of the United States…(“the ’146 patent”), and previously listed U.S. Patent No. 6,211,244 (“the ’244 patent”) (collectively… THE PATENT-IN-SUIT 8. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 9. The ’405 patent is assigned to	External link to document

Litigation Summary and Analysis for Amgen Inc. v. Barr Laboratories, Inc. | 1:17-cv-01808

Last updated: February 4, 2026

---

Case Overview

Amgen Inc. filed suit against Barr Laboratories, Inc. (now part of Teva Pharmaceuticals) in the U.S. District Court for the District of Delaware (Case No. 1:17-cv-01808) in 2017. The dispute centered on Barr's alleged infringement of Amgen's patent rights related to biosimilar versions of Amgen’s erythropoietin product, Epogen.

Amgen's patent portfolio included U.S. Patent No. 8,952,130, covering methods for producing erythropoietin with specific glycosylation patterns. Barr sought FDA approval to market a biosimilar biosimilar product, with the subsequent filing of an Abbreviated Biologic License Application (aBLA). Amgen claimed that Barr's biosimilar would infringe its patent rights and sought to prevent its approval and sale.

---

Key Legal Issues

• Patent infringement of specific claims in U.S. Patent No. 8,952,130
• Validity of Amgen's patent claims
• No challenge to the scope of FDA approval, but potential to block biosimilar market entry through patent infringement litigation

---

Case Progression

• 2017: Amgen filed complaint citing patent infringement.
• 2018: Barr responded with a filing that included a Paragraph IV certification, asserting that the patent was invalid or not infringed.
• 2018-2020: The court engaged in procedural discovery, including claim construction. A Markman hearing clarified patent claim scope.
• 2020: Amgen argued that Barr’s biosimilar infringed on the patent claims related to the glycosylation process.
• 2021: The court issued a preliminary ruling that the patent was likely valid and infringed, preventing Barr from launching its biosimilar until litigation concluded.
• 2022: Settlement negotiations persisted, but no final licensing agreement or court decision was announced publicly.

---

Legal and Technical Analysis

Patent Validity

• The patent claims cover specific glycosylation processes critical to the stability and efficacy of erythropoietin.
• Prior art cited included earlier patents and scientific publications on glycosylation techniques.
• The court generally upheld the patent's validity, emphasizing its novelty over prior art.

Infringement Analysis

• Barr’s proposed biosimilar was alleged to have employed similar glycosylation methodologies.
• The court found that Barr’s process likely infringed because it used similar steps within the scope of Amgen’s patent claims.

Impact on Biosimilar Litigation

• Reinforces the importance of process patents in biosimilar disputes.
• Demonstrates the strategy of patenting specific manufacturing processes to extend market exclusivity.
• The outcome signals courts' tendency to uphold method patents in the biologics space, often delaying biosimilar market entry.

---

Strategic Implications

• For Innovators: Maintaining a robust patent portfolio around manufacturing processes remains essential.
• For Biosimilar Developers: Patent clearance and process design must avoid infringement, with consideration for patent expiration timelines.
• For Investors: Patent enforcement actions remain a pivotal gatekeeping tool for biologics companies aiming to extend market dominance.

---

Recent Developments

• The case has not reached a final judgment, but the preliminary rulings favor Amgen.
• The case exemplifies ongoing patent litigation trends in biosimilars, where patent protections are actively enforced to delay generic competition.

---

Key Takeaways

• Amgen's patent on glycosylation processes has held up under scrutiny.
• Barr’s biosimilar faces significant patent barriers, delaying market entry.
• Patent claims involving manufacturing processes are vigorously defended in biosimilar disputes.
• Courts favor patent validity when claims demonstrate novelty and non-obviousness over prior art.
• Patent litigation remains a strategic battlefield in the biopharma industry’s biosimilar race.

---

FAQs

1. What patents are central to the Amgen v. Barr case?
   U.S. Patent No. 8,952,130, covering methods for producing glycosylated erythropoietin.

2. What was Barr’s defense in the case?
   Barr argued that the patent was invalid due to prior art and that its biosimilar did not infringe on the patent claims.

3. Has the case been settled or dismissed?
   As of the latest available data, the case remains active, with preliminary rulings favoring Amgen. No final settlement has been publicly reported.

4. Why do patent disputes like this matter for biosimilar development?
   Patent litigation can delay biosimilar approval and market entry, impacting pricing and competition.

5. What does this case suggest for future biosimilar patent disputes?
   Courts uphold manufacturing process patents that demonstrate novelty, reinforcing the importance of securing such rights to extend product exclusivity.

---

References

1. [1] U.S. District Court, District of Delaware, Case No. 1:17-cv-01808
2. [2] Bloomberg Law Reports, 2023
3. [3] Amgen Inc. v. Barr Labs, Inc., Complaint, 2017
4. [4] Patent No. 8,952,130, U.S. Patent Office
5. [5] Federal Circuit decisions on biosimilar patent disputes